Dillan Madhani

London UK

Contact Me Today

Dillan is an Associate in the Corporate and Life Sciences group in London. He specialises in advising companies and investors in the technology and life sciences sector on venture capital investments, M&A transactions and general corporate matters.

CV

Since 2024 Associate, Taylor Wessing

2022 - 2024 Trainee Solicitor, Taylor Wessing

2022 - 2022 Paralegal, Taylor Wessing

Career

Since 2024 Associate, Taylor Wessing

2022 - 2024 Trainee Solicitor, Taylor Wessing

2022 - 2022 Paralegal, Taylor Wessing

Education

2024 Admitted as a lawyer, England and Wales

2022 Master of Laws, BPP University (London)

2022 Legal Practice Course, BPP University (London)

Dillan's news & insights

View Dillan's insights

Click here to find out more

Corporate/M&A & capital markets

Advising Rezolve AI on its US$230 million acquisition of Reward Loyalty UK Limited

12 February 2026

by multiple authors

Corporate/M&A & capital markets

Advising Lingotto on its extended Series A funding into Optalysys to US$60 million

6 February 2026

by multiple authors

Click here to find out more

Expertise

Services and Groups

Sectors

CV

Career

Education

Dillan's news & insights

Advising Rezolve AI on its US$230 million acquisition of Reward Loyalty UK Limited

Dillan Madhani

Expertise

Services and Groups

Sectors

CV

Career

Education

Dillan's news & insights

Advising Rezolve AI on its US$230 million acquisition of Reward Loyalty UK Limited

Related news & insights

Taylor Wessing strengthens Corporate/M&A practice with Equity Partner Jan Hückel

Carbon Border Adjustment Mechanism (CBAM): From Reporting to Real Financial Impact

Request for a Preliminary Ruling by Federal Court of Justice on the Prohibition of Advertising for Remote Medical Treatments under Section 9 HWG

Sustainability Stories: Notpla

EU Inc. – The 28th Regime: How the European Commission intends to revolutionise the formation of companies

Consumer and Retail in the News

Prediction Markets in Germany and Europe: Legal Status, Risks, and Opportunities

Investing in the German Audit and Tax Advisory Market – Opportunity Amid Regulatory Debate

More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies

Advising on Tropic Biosciences' US$105 million Series C financing

Related people

Meet me at